Compare XYF & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XYF | DCTH |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.6M | 289.2M |
| IPO Year | 2018 | N/A |
| Metric | XYF | DCTH |
|---|---|---|
| Price | $7.14 | $10.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $22.60 |
| AVG Volume (30 Days) | 241.7K | ★ 739.3K |
| Earning Date | 11-20-2025 | 11-04-2025 |
| Dividend Yield | ★ 7.87% | N/A |
| EPS Growth | ★ 49.84 | N/A |
| EPS | ★ 5.72 | 0.03 |
| Revenue | ★ $1,106,908,607.00 | $79,603,000.00 |
| Revenue This Year | N/A | $131.97 |
| Revenue Next Year | N/A | $38.84 |
| P/E Ratio | ★ $1.21 | $300.67 |
| Revenue Growth | 47.14 | ★ 251.54 |
| 52 Week Low | $6.47 | $8.12 |
| 52 Week High | $20.36 | $18.23 |
| Indicator | XYF | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 29.63 | 62.85 |
| Support Level | $6.68 | $9.59 |
| Resistance Level | $6.98 | $10.14 |
| Average True Range (ATR) | 0.41 | 0.44 |
| MACD | 0.12 | 0.16 |
| Stochastic Oscillator | 45.86 | 87.15 |
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.